Wei et al., 2013 - Google Patents
No association betweenIL28Bgenotype and response to peginterferon alfa-2a (40KD) in HBe antigen-positive and HBe antigen-negative patients with chronic hepati …Wei et al., 2013
- Document ID
- 14708333940115568593
- Author
- Wei L
- Wedemeyer H
- Liaw Y
- Chan H
- Piratvisuth T
- Marcellin P
- Jia J
- Tan D
- Chow W
- Brunetto M
- Diago M
- Gurel S
- Morozov V
- He H
- Zhu Y
- Wat C
- Thompson A
- Publication year
- Publication venue
- Hepatology
External Links
Snippet
Background: It is yet to be firmly established whether host IL28B genotype influences the response to peginterferon alfa-2a (40KD)(PegIFN) in patients with chronic hepatitis B (CHB). Associations between markers of host IL28B genotype (rs8099917, rs12980275 …
- 208000002672 hepatitis B 0 title abstract description 20
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Al Mahtab et al. | Treatment of chronic hepatitis B naïve patients with a therapeutic vaccine containing HBs and HBc antigens (a randomized, open and treatment controlled phase III clinical trial) | |
| Nevens et al. | Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study | |
| Filippelli et al. | Hepatitis B vaccine by intradermal route in non responder patients: an update | |
| Cooksley et al. | Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B | |
| Malik et al. | Chronic hepatitis B virus infection: treatment strategies for the next millennium | |
| Lok | Hepatitis B infection: pathogenesis and management | |
| Lavanchy | Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures | |
| Kao | HB eAg‐positive chronic hepatitis B: why do I treat my patients with pegylated interferon? | |
| Pérez‐Cameo et al. | New therapeutic perspectives in HBV: when to stop NA s | |
| Hoa et al. | Randomized controlled study investigating viral suppression and serological response following pre-S1/pre-S2/S vaccine therapy combined with lamivudine treatment in HBeAg-positive patients with chronic hepatitis B | |
| Akbar et al. | A phase III clinical trial with a therapeutic vaccine containing both HBsAg and HBcAg administered via both mucosal and parenteral routes in patients with chronic hepatitis B: 923 | |
| Pol et al. | Therapeutic vaccination in chronic hepatitis B virus carriers | |
| Vlachogiannakos et al. | Optimal therapy of chronic hepatitis B: how do I treat HBeAg‐positive patients? | |
| Bazinet et al. | Significant reduction of HBsAg and HDV RNA by the nucleic acid polymer REP 2139 in Caucasian patients with chronic HBV/HDV co-infection | |
| Akbar et al. | Immune therapies against chronic hepatitis B | |
| Liu et al. | Hepatitis B: treatment choice and monitoring for response and resistance | |
| US20220370447A1 (en) | Method of treating hbv infection using a core protein allosteric modulator | |
| Wei et al. | No association betweenIL28Bgenotype and response to peginterferon alfa-2a (40KD) in HBe antigen-positive and HBe antigen-negative patients with chronic hepati-tis B in three large randomized clinical studies: 924 | |
| Lee et al. | Efficacy and safety of entecavir versus lamivudine over 5 years of treatment: a randomized controlled trial in Korean patients with hepatitis B e antigen-negative chronic hepatitis B | |
| Durantel et al. | Nucleic acid polymers are effective in targeting hepatitis B surface antigen, but more trials are needed | |
| Lim et al. | Clinical trial: effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B | |
| Bazinet et al. | REP 2139 monotherapy and combination therapy with pegylated interferon: safety and potent reduction of HBsAg and HDV RNA in Caucasian patients with chronic HBV/HDV co-infection | |
| Ma et al. | Why do I treat HBeAg‐positive chronic hepatitis B patients with a Nucleoside analogue | |
| Aguilar et al. | Therapeutic Vaccination in Chronic Hepatitis B: A Systematic Assessment by the HeberNasvac Therapeutic Vaccine Team | |
| Scott et al. | Role of combination therapy in chronic hepatitis B |